Minnelide, a drug that has successfully completed Phase 1 trial and is awaiting Phase 2 trial has shown remarkable effect in downregulating a number of key pancreatic cancer pathways like Sp1 and NF-kB mediated signaling. This evidence concerns the gene SP1 and familial pancreatic carcinoma.